Zeng Hongmei, Zheng Rongshou, Sun Kexin, Zhou Maigeng, Wang Shaoming, Li Li, Chen Ru, Han Bingfeng, Liu Meicen, Zhou Jinhui, Xu Mengyuan, Wang Lijun, Yin Peng, Wang Baohua, You Jinling, Wu Jing, Wei Wenqiang, He Jie
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
J Natl Cancer Cent. 2024 Jun 22;4(3):203-213. doi: 10.1016/j.jncc.2024.06.005. eCollection 2024 Sep.
A milestone goal of the Healthy China Program (2019-2030) is to achieve 5-year cancer survival at 43.3% for all cancers combined by 2022. To assess the progress towards this target, we analyzed the updated survival for all cancers combined and 25 specific cancer types in China from 2019 to 2021.
We conducted standardized data collection and quality control for cancer registries across 32 provincial-level regions in China, and included 6,410,940 newly diagnosed cancer patients from 281 cancer registries during 2008-2019, with follow-up data on vital status available until December 2021. We estimated the age-standardized 5-year relative survival overall and by site, age group, and period of diagnosis using the International Cancer Survival Standard Weights, and quantified the survival changes to assess the progress in cancer control.
In 2019-2021, the age-standardized 5-year relative survival for all cancers combined was 43.7% (95% confidence interval [CI], 43.6-43.7). The 5-year relative survival varied by cancer type, ranging from 8.5% (95% CI, 8.2-8.7) for pancreatic cancer to 92.9% (95% CI, 92.4-93.3) for thyroid cancer. Eight cancers had 5-year survival of over 60%, including cancers of the thyroid, breast, testis, bladder, prostate, kidney, uterus, and cervix. The 5-year relative survival was generally lower in males than in females. From 2008 to 2021, we observed significant survival improvements for cancers of the lung, prostate, bone, uterus, breast, cervix, nasopharynx, larynx, and bladder. The most significant improvement was in lung cancer.
Progress in cancer control was evident in China. This highlights the importance of a comprehensive approach to control and prevent cancer.
《健康中国行动（2019—2030年）》的一个里程碑式目标是到2022年实现所有癌症的5年综合生存率达到43.3%。为评估朝着这一目标取得的进展，我们分析了2019年至2021年中国所有癌症以及25种特定癌症类型的最新生存率。
我们对中国32个省级行政区的癌症登记处进行了标准化数据收集和质量控制，纳入了2008年至2019年期间来自281个癌症登记处的6410940例新诊断癌症患者，并获得了截至2021年12月的生命状态随访数据。我们使用国际癌症生存标准权重估计了总体以及按部位、年龄组和诊断时期划分的年龄标准化5年相对生存率，并对生存率变化进行量化以评估癌症控制方面的进展。
在2019年至2021年期间，所有癌症综合的年龄标准化5年相对生存率为43.7%（95%置信区间[CI]，43.6 - 43.7）。5年相对生存率因癌症类型而异，从胰腺癌的8.5%（95%CI，8.2 - 8.7）到甲状腺癌的92.9%（95%CI，92.4 - 93.3）不等。八种癌症的5年生存率超过60%，包括甲状腺癌、乳腺癌、睾丸癌、膀胱癌、前列腺癌、肾癌、子宫癌和宫颈癌。男性的5年相对生存率总体低于女性。从2008年到2021年，我们观察到肺癌、前列腺癌、骨癌、子宫癌、乳腺癌、宫颈癌、鼻咽癌、喉癌和膀胱癌的生存率有显著提高。改善最为显著的是肺癌。
中国在癌症控制方面取得了明显进展。这凸显了采取综合方法控制和预防癌症的重要性。
